Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy
A landmark randomized controlled trial which showed that, compared to placebo, losartan reduced the incidence of a doubling of the serum creatinine concentration and end-stage renal disease.
- Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes
- Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes